Jump to:
David Marino is an associate in the corporate department at Ropes & Gray. He advises clients on a variety of corporate transactions and governance matters with a primary focus on mergers and acquisitions and venture capital. Prior to joining Ropes & Gray, David was an associate in the emerging companies and venture capital group at another international law firm in Boston.
Experience
- Represented Pfizer Inc. in its $6.7 billion acquisition of Arena Pharmaceuticals, Inc.
- Represented Scipher Medicine Corporation, a precision immunology company matching patients with the most effective therapy, in its $110 million Series D financing led by Cowen Healthcare Investments.
- Represented Population Health Partners in the formation and Series A financing of Areteia Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on asthma medication, in collaboration with Knopp Biosciences and with a commitment to invest up to $350 million by Bain Capital Life Sciences and a syndicate of leading life sciences and strategic investors.
- Represented Aera Therapeutics, Inc., a biotechnology company focused on the development of CRISPR delivery technology, in its $193 million combined Series A and Series B financings led by ARCH Venture Partners, GV and Lux Capital.
- Represented Jounce Therapeutics, a clinical-stage immuno-oncology company, in its acquisition by Concentra Biosciences for $100 million plus contingent value rights.
- Represented American Society of Clinical Oncology in the sale of CancerLinQ to ConcertAI.
- Represented Lassen Therapeutics, Inc., a clinical stage biotechnology company focused on developing antibody biotherapeutics for treatment of cancer and inflammatory diseases, in its $85 million Series B financing led by Frazier Life Sciences and Longitude Capital.
- Represented Areteia Therapeutics, Inc. in the $75 million expansion of its Series A financing.
- Represents various venture capital, institutional and strategic investors in venture and growth equity investments.